Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria.
Hematologic Toxicity
Linezolid
MDR-TB
Mitochondria
XDR-TB
Journal
Tuberculosis and respiratory diseases
ISSN: 1738-3536
Titre abrégé: Tuberc Respir Dis (Seoul)
Pays: Korea (South)
ID NLM: 101479418
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
07
08
2021
accepted:
16
01
2022
pubmed:
21
1
2022
medline:
21
1
2022
entrez:
20
1
2022
Statut:
ppublish
Résumé
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018, the World Health Organization revised the groupings of TB medicines and reclassified linezolid as a group A drug for the treatment of MDR-TB. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Although linezolid has a good efficacy, it can cause substantial adverse events, especially hematologic toxicity. In both TB infection and linezolid mechanism of action, mitochondrial dysfunction plays an important role. In this concise review, characteristics of linezolid as an anti-TB drug are summarized, including its efficacy, pathogenesis of hematologic toxicity highlighting mitochondrial dysfunction, and the monitoring and management of hematologic toxicity.
Identifiants
pubmed: 35045688
pii: trd.2021.0122
doi: 10.4046/trd.2021.0122
pmc: PMC8987663
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
111-121Subventions
Organisme : Universitas Padjadjaran
ID : 1595/UN6.3.1/PT.00/2021
Organisme : Universitas Padjadjaran
ID : 3855/UN.C/LT/2019
Références
N Engl J Med. 2003 Jan 2;348(1):86-7
pubmed: 12510056
Br J Clin Pharmacol. 2017 Aug;83(8):1758-1772
pubmed: 28186644
Clin Infect Dis. 2005 Jun 15;40(12):e113-6
pubmed: 15909253
Antimicrob Agents Chemother. 2007 Mar;51(3):962-7
pubmed: 17194826
N Engl J Med. 2012 Oct 18;367(16):1508-18
pubmed: 23075177
J Thorac Dis. 2015 Apr;7(4):603-15
pubmed: 25973226
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142
pubmed: 31729908
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263063
N Engl J Med. 2005 Nov 24;353(21):2305-6
pubmed: 16306535
Infection. 2014 Dec;42(6):1007-12
pubmed: 25119433
Ann Clin Microbiol Antimicrob. 2016 Jun 22;15(1):41
pubmed: 27334498
Antimicrob Agents Chemother. 2002 Aug;46(8):2723-6
pubmed: 12121967
Int J Antimicrob Agents. 2013 Jun;41(6):586-9
pubmed: 23562639
J Infect Chemother. 2011 Jun;17(3):382-7
pubmed: 21127934
Int J Mycobacteriol. 2016 Dec;5(4):379-383
pubmed: 27931677
Clin Infect Dis. 2002 Mar 1;34(5):695-8
pubmed: 11803505
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
Semin Immunol. 2009 Aug;21(4):223-32
pubmed: 19535268
Mucosal Immunol. 2011 May;4(3):279-87
pubmed: 21307848
J Antimicrob Chemother. 2004 Oct;54(4):832-5
pubmed: 15317746
Apoptosis. 2015 Jul;20(7):883-91
pubmed: 25840680
Eur Respir J. 2019 Dec 4;54(6):
pubmed: 31439686
Int J Tuberc Lung Dis. 2012 Apr;16(4):447-54
pubmed: 22325685
Biol Pharm Bull. 2016;39(11):1846-1851
pubmed: 27803456
J Antimicrob Chemother. 2012 Jun;67(6):1503-7
pubmed: 22403262
Eur Respir J. 2012 Dec;40(6):1430-42
pubmed: 22496332
Clin Infect Dis. 2003 Jan 15;36(2):159-68
pubmed: 12522747
Int J Tuberc Lung Dis. 2019 Dec 1;23(12):1293-1307
pubmed: 31931914
Lancet. 2018 Sep 8;392(10150):821-834
pubmed: 30215381
Can J Infect Dis Med Microbiol. 2013 Fall;24(3):e50-2
pubmed: 24421829
Scand J Immunol. 2003 Oct;58(4):419-27
pubmed: 14507307
Microbes Infect. 2015 Oct;17(10):689-97
pubmed: 26092385
J Antimicrob Chemother. 2005 Aug;56(2):440-1
pubmed: 15956097
Antimicrob Agents Chemother. 2013 Sep;57(9):4097-104
pubmed: 23774431
Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335
pubmed: 30496467
Pharmacotherapy. 2001 Aug;21(8):1010-3
pubmed: 11718489
Eur Respir J. 2015 Jan;45(1):161-70
pubmed: 25234807
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28674062
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1511-1517
pubmed: 28343274
Oncology (Williston Park). 2000 Aug;14(8 Suppl 6):23-9
pubmed: 10989821
Clin Infect Dis. 2004 Aug 1;39(3):439
pubmed: 15307017
Infect Dis Clin North Am. 2003 Sep;17(3):479-501
pubmed: 14711073
J Immunol. 2006 Mar 15;176(6):3707-16
pubmed: 16517739
Ann Pharmacother. 2003 Apr;37(4):517-20
pubmed: 12659607
Expert Opin Pharmacother. 2015;16(18):2737-50
pubmed: 26478945
Clin Infect Dis. 2002 Aug 1;35(3):E29-31
pubmed: 12115113
J Infect Dev Ctries. 2019 Oct 31;13(10):886-891
pubmed: 32084018
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv7-iv15
pubmed: 21521707
Drug Des Devel Ther. 2018 Jun 18;12:1759-1767
pubmed: 29950810
Clin Ther. 2009 Oct;31(10):2126-33
pubmed: 19922883
Tuberculosis (Edinb). 2014 Mar;94(2):93-104
pubmed: 24388605
J Infect Chemother. 2016 Aug;22(8):536-42
pubmed: 27321773
J Antimicrob Chemother. 2004 Oct;54(4):798-802
pubmed: 15329363
Curr Ther Res Clin Exp. 2012 Dec;73(6):195-206
pubmed: 24653521
J Int Med Res. 2018 Nov;46(11):4837-4844
pubmed: 30270705